Fierce Biotech

After a decade of hype, Najat Khan is bringing Recursion back down to earth

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
pharmaphorum

Recursion, Exscientia, and AI drug discovery’s moment of truth

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
pharmaphorum

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Investopedia

Quantitative Investment Strategies: Models, Algorithms, and Techniques

Michael Schmidt, CFA, is a staff member of FINRA's Dispute Resolution Board with 20+ years of experience in the financial market. Doretha Clemons, Ph.D., MBA, PMP, has been a corporate IT executive ...